Recently, stem cell research has gained great public interest and different cell-based clinical trials have started in Iran. The objective of this study was to provide an overview of clinical cell transplantation researches in Iran, which has assumed a leadership role in the Middle East. Evidence Acquisitions: To evaluate the state of clinical cell transplantation researches in Iran, we conducted a literature review on December 1, 2011 using PubMed, IranMedex, US NIH registry for clinical trials and Iranian registry of clinical trials (IRCT).We used "Cell", "Cells", "Cell Transplantation", and "Iran" as keywords to identify stem cell related research articles or projects. Publications were then examined manually to exclude those that did not use stem cells in a clinical setting or did not report original research. Hard copy of all related articles were used to extract the following data: the year of publication, journal's name, number of authors, cell type, processing method, subject, and study design. Results: Twenty one articles and 33 registered trials were related to clinical application of cellular products. Except for 6 articles, the others were multicenteral. The main subject of articles was cardiovascular diseases (23.52%) and for registered clinical trials this was osteoarticular disorders (24.24%). Bone marrow derived mesenchymal stem cells (BM-MSC) and mononuclear cells (BM-MNC) were the most frequent cell types in these trials. From 12 completed trials only 4 have been reported in medical journals. Conclusions: By comparison with basic stem cell research, the current status of cell transplantation trials in Iran is not optimal. Joined multicenteral research, establishment of national regulations, sharing of facility and staff, international collaborations and bridging the gap between basic and clinical research may improve quality and quantity of clinical cell transplantation research in Iran.
Context
Cell-based therapies have grown dramatically in power and scope during the recent years. Once limited to blood and BM transplantation, these therapies now encompass tissue repair and regeneration, metabolic support, gene replacement, and immune effector functions, with established and investigational clinical applications in disorders affecting nearly every tissue (1) . Transplantation activities in Iran started in 1935, when the first corneal transplantation was performed, followed by kidney (1968) , bone marrow (1991), liver and heart (1993), lung (2000) and pancreas (2006) (2) . Although, Hematopoietic Stem Cell Transplantation (HSCT)started in 1991, the history of novel cell-based therapies is less than 10 years (3, 4). Iran's government has actively promoted science and technology in an attempt to enhance the country's global status (5) . In 2005, the Ministry of Health and Tehran University of Medical Sciences jointly developed a set of guidelines regarding research on gametes and embryos which permitted the use of human embryos for stem cell research and therapy under certain circumstances (6) . Based on a recent report, stem cell clinical trials in the Middle East have more than quadrupled to over 400 registered clinical trials in January 2010. Countries such as Saudi Arabia and Qatar have founded nascent programs while Iran is more established in the field (7) . In the recent decade, stem cell research has become one of the most important and dynamic fields of biomedical research. The annual number of articles devoted to stem cell research has increased by more than seven-folds during the last 16 years (8) . Quantification of scientific productivity of a country can reflect its research status in a specific field and may affect the decision-making process by research policy makers (9, 10) . Recently, two reports tried to describe the status of stem cell research in Iran (11, 12) . One of them reported on the clinical aspect of stem cell research, focusing on NIH-registered clinical trials. This report only reflected part of the actual work in this field, because there are some other published trials that have not been registered in clinical trial registries. The intention of this paper is to provide an overview of registered and published clinical cell transplantation researches in Iran, which has assumed a leadership role in the Middle East. In the current study, cell preparation methods, GMP compliance and quality testing are reviewed.
Evidence Acquisitions
The authors conducted a literature review of publications on December 1, 2011 using PubMed (www.ncbi.nlm. nih.gov) as international and IranMedex (http://www. iranmedex.com) as a national database. To investigate the status of ongoing or unpublished researches, US NIH registry for clinical trials (http://www.clinicaltrials.gov) and Iranian registry of clinical trials (IRCT-http://www.irct.ir) were included. IranMedex is a local database, which consists of 231 journals and 72791 articles at the time of study. It covers all publications of Iranian biomedical journals registered and indexed in Iran's ministry of health. IRCT is a primary registry in the WHO Registry Network that has been set up with help from the Ministry of Health and Medical Education (MOHME) and is hosted by Tehran University of Medical Sciences (TUMS). We used "Cell", "Cells", "Cell Transplantation", and "Iran" as keywords to identify stem cell related research articles or clinical trials. Publications were then examined manually to exclude those that did not use stem cells in a clinical setting or did not report original research. HSCT for hematological disorders and malignancies were also excluded. Hard copies of all related articles were used to extract the following data: the year of publication, journal's name, number of authors, authors' affiliation, subject, cell type, cell processing method, and quality testing.
Results
The PubMed search resulted in 17 articles related to clinical cell transplantation. In IranMedex, only 4 articles were related to the research topic. The average number of authors per article was 8.90 and the average of affiliation was 3.90 per article. All authors were Iranian and only in 2 articles a foreign country was used as a second affiliation. Except for 6 articles, the others were multicenteral. The main subject of articles was cardiovascular disease (23.52%), followed by liver disease (17.64%), neurological disorders (17.64%), skin lesions (11.76%), oral pathologies (11.76%) and other conditions (17.64%) ( Table 1) . The most frequent cell types for these trials were BM-MSC (41.17%) and BM-MNC (17.64%) respectively. In 6 articles, the cell products had been manufactured in GMP facilities (i.e. a cleanroom) which were affiliated to the Brain and Spinal Injury Repair Research Center (TUMS) and the Royan institute. Autologous human serum had been used as a substitute for fetal bovine sera (FBS) for culturing Schwann cells and BM-MSCs in 3 articles. The country of origin for FBS was not identified in published articles. Microbiological studies should be performed routinely during different steps of cell manufacturing, however only 7 articles reported doing these tests. The most frequent cell transplant solution was normal saline supplemented with 1% human serum albumin. Other transplant solutions were: autologous serum, autologous plasma, medium 199 and melanocyte growth medium (MGM-M2). Table 1 represents detailed informationabout the published articles in PubMed. From the 33 registered clinical trials, 8 were registered in the IRCT website and 25 in the US NIH registry ( Table 2 ). The main condition was osteoarticular disorders (26.67%) followed by liver disease (16.67%), diabetes (13.33%), cardiovascular diseases (13.33%), skin lesions (13.33%), neurological disorders (10%), and other conditions (6.67%). In 2 trials, adult BM-MSCs and fetal hematopoietic stem cells were used as allograft transplants (NCT00515307 and IRCT138811071414N10). Differentiated
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Arjmand B et al. 9 Arch Neurosci. 2014; 1 (1) BM-MSCs were considered in 2 trials (NCT00515307 and IRCT201107221696N3). From 18 published trials, only 4 had been previously registered.
Conclusions
While cell-based therapies are the clinical standard of care for a few conditions, such as HSCT for hematological disorders and epithelial cell transplantation for burns (12) . The current study revealed that despite rapid growth of basic stem cell research in Iran a small number of publications were related to their clinical applications. This may be due to many factors such as: complexity of cell manufacturing for clinical application, inappropriate facilities, insufficient human and financial recourses, safety concerns, lack of legislation and validated pre-clinical studies. The gap between basic scientists and clinicians is another obstacle in the way of clinical and translational stem cell research. To bridge this gap, we need someone with a medical background and basic science experience that is familiar with GMP rules and quality management system. In this model of collaboration the responsibility of each party has to be well defined and overlaps minimized. As seen in Tables 1  and 2 , the most frequent cell type is BM-MSC. The safety and biological properties of MSC rapidly led to the investigation of their use in cell-based therapy by the middle of the 1990s. More than 260 clinical trials related to MSCs have been registered with the US NIH registry. Thus it is not surprising that these are the cells of interest in clinical trials (14) . There are different protocols for isolation and expansion of BM-MSC in published trials, therefore, it is difficult to compare and contrast study outcomes. To address this problem, in 2006, the International Society for Cellular Therapy (ISCT) proposed minimal criteria to define human MSC for both laboratory-based scientific investigations and pre-clinical studies (15) . In the current study, none of the published trials fulfilled these criteria for MSC characterization. Although these minimal criteria are intended for research purposes, it can be used to standardize different cell preparation protocols. Except for 3 articles, FBS have been used as serum supplements in culture protocols. When applicable, animal-derived reagents should be replaced by animal-free products. Human platelet lysate, autologous serum and pooled human serum have been suggested by different studies as alternatives to FBS (1, (16) (17) (18) (19) . Another animal derived reagent that has been applied for cell detachment is Trypsin. TrypLE (Invitrogen) and TrypZean (Sigma-aldrich) have been suggested as two animal origin-free alternatives for porcine Trypsin (20) . We have successfully utilized TrypLE for dissociation of BM-MSC, Adipose tissue derived MSC and Schwann cell and recommend it for clinical grade cell preparation (unpublished data). If animal products cannot be replaced, they should be sourced in a controlled and documented manner and from animals bred and raised in captivity in countries or geographic regions that have appropriate national health status, disease prevention, and control systems (The United States Pharmacopeial Convention 2008). According to the current European law and FDA regulations, cell-based products should be manufactured under principles of GMP when they are used in phase I studies (21) . Only 6 articles noted that cell preparations had been performed in a clean room facility. It should be considered that establishment and maintenance of a clean room is a complex procedure that needs technical expertise and considerable financial support. Therefore, collaboration with an existing GMP facility may be more cost-effective for centers with limited resources (22) . The final cell product to be administered, as well as the production process and materials used, should be subjected to quality control testing. In this study, the average number of authors and affiliations per article were 8.90 and 3.90 respectively. Collaboration with a well-established laboratory may provide a mechanism for newer and less well-known researchers to network within the stem cell research community. It has been proposed that the number of authors on a paper increases the citation rate simply due to increased selfcitation (7). Although there was not any international collaboration, most of the publications were multi-institutional. Prior studies on stem cell research in the Middle East suggest that international collaborations resulted in stem cell publications with a higher citation rate than articles published by a single nation from the region (23) . Another research has established that articles with authors from multiple countries were cited twice as frequently as publications authored by scientists working at a single institution or within a single country. Although citation rate is not the best way to measure quality, but it is the simplest quantitative measure of publication quality that is used across disciplines and across national contexts (7); ( The present study describes the status of clinical cell transplantation research in Iran. The authors suggest that more comprehensive studies should be conducted to make a detailed map of stem cell research in this country. The growing trend towards stem cell research and transplantation in this country will open new horizons for treatment of incurable diseases. However, this raises safety and ethical concerns that necessitate strict supervision by regulatory agencies. To reduce these concerns, Iranian council of stem cell technology was established in 2008. Its main goal is the promotion of clinical and translational stem cell researches in order to improve public health. The authors suggest that this council should play an active role in regulation of cell therapies. This can be achieved by collaboration with other regulatory bodies (such as Food and Drug Organization) and preparation of national guidelines for clinical cell transplantation. Financial limitations and sanctions are the main barriers against stem cell research and therapy in Iran. Sanctions increase purchasing cost and time because they prevent the direct purchasing of materials and equipment from the main suppliers that are located in foreign countries. On the other hand, clinical grade cell manufacturing needs clinical grade reagents, specialized instruments, strict quality testing, and proper facilities (i.e. a cleanroom). Therefore, the primary costs of cell transplantation are higher than other conventional therapies. To perform a cost-effective procedure, stem cell research priorities should be set by research centers, paying attention to health system priorities. In conclusion, joined multicenter research, international collaborations, establishment of national regulations, well designed preclinical studies, adhering to international standards, sharing of facilities and staff, and bridging the gap between basic and clinical research may improve quality and quantity of clinical cell transplantation research in Iran.
